What is the latest status of the project “BioChina”?

The status recorded for “BioChina” is completed.

Who are the main government, EPC, and private stakeholders for “BioChina”?

Taiyo maps the stakeholders of “BioChina”: government bodies (International Finance Corporation (IFC)).

Where can I verify the source and access all details for “BioChina”?

This Taiyo project page references International Finance Corporation (IFC) along with the original URL (https://disclosures.ifc.org/project-detail/SPI/23574/biochina). Taiyo standardizes official data into a consistent, searchable project profile.

BioChina

Sector: Bridge • Location: China

Source: International Finance Corporation (IFC)

Project

Completed

IFC is considering an equity commitment of up to $5 million to the BioVeda China Fund (the fund or BioChina), an investment vehicle to be established by a select group of institutional investors, to invest in Chinese biotech and life sciences companies. The Fund will be managed by BioVeda Capital (the manager or BioVeda), a Singapore/US headquartered biotech investment firm which currently manage

Project Information

4 Q

The project “BioChina” is an infrastructure initiative in the Bridge sector, located in China. Taiyo aggregates data on it from International Finance Corporation (IFC).

Want to explore the full details? View the full report

Participants

Sponsoring Agency	Obfuscated Data
Company	Obfuscated Data

Status

Original status	completed
Taiyo status	Obfuscated Data
Taiyo last update	00-00-0000
Available timestamps	00-00-0000
Available timestamp type	Obfuscated Data

Contact

Contact name	Obfuscated Data
Phone	0000000000
Email	ObfuscatedData@email.com
Address	Obfuscated Data, Obfuscated data, obfuscated data, Obfuscated data

Description

Description	IFC is considering an equity commitment of up to $5 million to the BioVeda China Fund (the fund or BioChina), an investment vehicle to be established by a select group of institutional investors, to invest in Chinese biotech and life sciences companies. The Fund will be managed by BioVeda Capital (the manager or BioVeda), a Singapore/US headquartered biotech investment firm which currently manages a $32 million venture fund that has invested in the US and Asia. The fund is targeting a first closing in early 2005. BioChina targets to raise up to $25 million to be invested in 3-5 companies to whom the fund would provide both expansion capital and management expertise in order to help to grow their businesses significantly. Exits are expected to be achieved through a stock exchange listing or a strategic sale.
Original sub-sector	Obfuscated
Original Currency	USD
Original budget	000000000000000
Procurement method	Obfuscated Data
Budget	000000000000000

Location

Region	Obfuscated
Country	Obfuscated
State	Obfuscated Data
County	Obfuscated
Location	Obfuscated Data, Obfuscated data, obfuscated data, Obfuscated data

Source

Source reliability	High
Data quality score	100%
Source	Obfuscated Data
URL	obfuscated_data,obfuscateddata.com

More Details

Project Type	Obfuscated Data
Article Published Date	Obfuscated Data

BioChina

Project Information FAQ

Project Information